BME100 s2014:T Group14 L1
 BME 100 Fall 2013
|
Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | |||||
| ||||||
OUR TEAM
LAB 1 WRITE-UPThe goal is to find the lowest possible dosage of an IIA (inflammation inducing agent) drug to increase the levels of a newly discovered inflammitory protein contained in the blood. Using an ELISA test, it has been determined that 10mg of the IIA can induce an increase of the specific protein. Independent and Dependent VariablesThe independent variable is the dosage of lipopolysaccharide (LPS) which is inflammation inducing agent (IIA) that affects the levels of Inflammotin, an inflammatory protein in the blood. This is the independent variable because the dosage can be changed in order to get a different result when monitoring the Inflammotin levels. The dependent variable is the levels inflammatory protein called Inflammotin in the subjects’ blood. These level changes can be examined by taking blood sample, and the amount of this protein depends on the dosage of LPS given to the subjects. Experimental DesignTest subjects will be in the age range of 60-85 with an even distribution of genders among the groups (10 males and 10 females). The individuals will be screened prior to selection for STD’s, Heart conditions, Blood diseases, Neural diseases, and any other disqualifying condition that could interfere with the results of inflammation such as arthritis or neuropathy. Groups will be divided evenly so that no statistical difference, age or gender, exists between the groups. The test groups will be tested with a double-blind setup utilizing a placebo. Given that it is known that 10mg of the IIA will increase the inflammatory protein, dosage will decrease from 10mg until no observable change in inflammation is present. For each dosage decreasing by one mg (ex:10,9,8,7…) a group of 10 males and 10 females will be tested until a dosage is reached where no inflammatory change is observable. Once that dosage is reached, the dosage of IIA will be increased by a smaller increment until once again an inflammatory difference is observable. (Ex: 5,5.5,6,6.5…) That will optimize finding the lowest possible dosage to increase the inflammatory protein.
Subject SelectionHealthy and mentally fit elderly male and female with no prior disqualifying conditions. Test subjects must be able to have blood drawn multiple times with no fatigue from obtaining samples, therefore it is crucial to consider any pre-existing blood or heart conditions Subjects must be able to receive dosage at the same time for every administration. Considerations will also be made depending on the persons blood type, if it has previously been identified to be a factor that effects the affects of the drug.
Sources of Error and BiasBias will be encountered as a source of error in the process of conducting the experiment, it is important to ensure that all data is accurate, with the independent and dependent variables controlled, and the blood samples taken by different administrators to ensure no error. Faulty blood samples or contaminated blood samples can be avoided by running multiple tests on the subjects. Genetic predisposition towards the effects of the drug being tested can try to be bypassed by attempting to find the healthiest subjects to ensure data is as accurate as possible. For this, subjects can be prescreened for existing health conditions, but this doesn’t show what the subjects do not disclose. To avoid other errors regarding equipment, it is important to make sure that the equipment is cleaned. It is also important to control the when the pill is administered and when tests are taken on the subjects, this can ensure that the test is accurate and that the drug is sufficiently in the subjects system to get accurate results.
| ||||||
